Zacks Research Downgrades Maximus (NYSE:MMS) to Strong Sell

Maximus (NYSE:MMS) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued on Tuesday,Zacks.com reports.

Several other research firms have also commented on MMS. Wall Street Zen lowered shares of Maximus from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings downgraded Maximus from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 20th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Reduce”.

Maximus Price Performance

MMS opened at $54.45 on Tuesday. Maximus has a 1 year low of $52.73 and a 1 year high of $100.00. The company has a debt-to-equity ratio of 0.90, a current ratio of 2.42 and a quick ratio of 2.42. The company has a market capitalization of $2.85 billion, a price-to-earnings ratio of 8.04 and a beta of 0.59. The firm’s fifty day moving average price is $58.24 and its two-hundred day moving average price is $66.33.

Maximus (NYSE:MMS) last announced its earnings results on Thursday, August 6th. The health services provider reported $2.22 EPS for the quarter, beating the consensus estimate of $2.21 by $0.01. Maximus had a net margin of 7.07% and a return on equity of 24.91%. The company had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.33 billion. During the same quarter in the prior year, the company posted $2.16 earnings per share. The firm’s revenue for the quarter was down 5.1% on a year-over-year basis. Maximus has set its FY 2026 guidance at 7.900-8.200 EPS. As a group, analysts anticipate that Maximus will post 8.01 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Maximus

Several institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new stake in Maximus in the second quarter worth about $400,186,000. Dimensional Fund Advisors LP grew its position in shares of Maximus by 7.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,107,278 shares of the health services provider’s stock valued at $135,084,000 after acquiring an additional 141,362 shares during the period. Reinhart Partners LLC. grew its position in shares of Maximus by 131.8% during the 2nd quarter. Reinhart Partners LLC. now owns 1,982,415 shares of the health services provider’s stock valued at $106,575,000 after acquiring an additional 1,127,346 shares during the period. Geode Capital Management LLC increased its stake in shares of Maximus by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 1,482,079 shares of the health services provider’s stock worth $127,952,000 after purchasing an additional 5,130 shares during the last quarter. Finally, Van Berkom & Associates Inc. increased its stake in shares of Maximus by 3.7% during the 1st quarter. Van Berkom & Associates Inc. now owns 1,172,190 shares of the health services provider’s stock worth $75,137,000 after purchasing an additional 41,862 shares during the last quarter. Institutional investors own 97.21% of the company’s stock.

About Maximus

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.